DE69725739T2 - Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen - Google Patents

Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen Download PDF

Info

Publication number
DE69725739T2
DE69725739T2 DE69725739T DE69725739T DE69725739T2 DE 69725739 T2 DE69725739 T2 DE 69725739T2 DE 69725739 T DE69725739 T DE 69725739T DE 69725739 T DE69725739 T DE 69725739T DE 69725739 T2 DE69725739 T2 DE 69725739T2
Authority
DE
Germany
Prior art keywords
menb
antibodies
seam
antibody
molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69725739T
Other languages
German (de)
English (en)
Other versions
DE69725739D1 (de
Inventor
Dan Granoff
R. Gregory MOE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Childrens Hospital Oakland Research Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Childrens Hospital Oakland Research Center
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center, Childrens Hospital Oakland Research Center , Chiron Corp filed Critical Cincinnati Childrens Hospital Medical Center
Publication of DE69725739D1 publication Critical patent/DE69725739D1/de
Application granted granted Critical
Publication of DE69725739T2 publication Critical patent/DE69725739T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69725739T 1996-08-27 1997-08-27 Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen Expired - Lifetime DE69725739T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2579996P 1996-08-27 1996-08-27
US25799 1996-08-27
PCT/US1997/015167 WO1998008874A1 (en) 1996-08-27 1997-08-27 Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions

Publications (2)

Publication Number Publication Date
DE69725739D1 DE69725739D1 (de) 2003-12-11
DE69725739T2 true DE69725739T2 (de) 2004-08-05

Family

ID=21828119

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69725739T Expired - Lifetime DE69725739T2 (de) 1996-08-27 1997-08-27 Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen

Country Status (7)

Country Link
US (4) US6048527A (https=)
EP (1) EP0922059B1 (https=)
JP (2) JP4150082B2 (https=)
AT (1) ATE252602T1 (https=)
CA (1) CA2264585C (https=)
DE (1) DE69725739T2 (https=)
WO (1) WO1998008874A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ES2166097T5 (es) * 1996-08-27 2007-03-16 Novartis Vaccines And Diagnostics, Inc. Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
JP4150082B2 (ja) * 1996-08-27 2008-09-17 カイロン コーポレイション 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
ATE421527T1 (de) 1997-08-27 2009-02-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkus b epitopen
GB9823835D0 (en) * 1998-10-30 1998-12-23 Univ London Component for vaccine
JP2002536295A (ja) * 1998-12-14 2002-10-29 パラチン テクノロジーズ， インク． 金属ペプチド組合せライブラリ及びその利用法
MXPA01012787A (es) 1999-08-06 2005-08-26 Ivigene Corp Polinucleotidos microbianos expresados durante la infeccion de un huesped..
US7033748B2 (en) * 1999-08-06 2006-04-25 Ivigene Corporation Identification of microbial polynucleotides expressed during infection of a host
US7049398B1 (en) * 1999-08-12 2006-05-23 Palatin Technologies, Inc. Melanocortin metallopeptide constructs, combinatorial libraries and applications
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
US7189405B1 (en) * 1999-10-29 2007-03-13 Rice Peter A Peptide mimics of conserved gonococcal epitopes and methods and compositions using them
AU1623801A (en) * 1999-11-19 2001-05-30 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
PT2289545T (pt) * 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US7385025B2 (en) * 2000-12-19 2008-06-10 Palatin Technologies, Inc. Metallopeptide compounds
AU2002238106A1 (en) * 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US20020131953A1 (en) * 2001-03-14 2002-09-19 Ut Southwestern Medical Center In situ langerhans cell vaccine
EP1379272B1 (en) * 2001-04-17 2010-01-20 Novartis Vaccines and Diagnostics, Inc. Monoclonal antibodies directed against molecular mimetics of meningococcal b epitopes
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
KR100506118B1 (ko) * 2002-04-19 2005-08-04 학교법인연세대학교 수막염균증 백신 조성물
EP1411061A1 (en) * 2002-10-16 2004-04-21 Centre National De La Recherche Scientifique (Cnrs) Poly-alpha2,8-sialic acid mimetic peptides and their application
CA2530364C (en) * 2003-06-23 2014-03-18 Baxter International Inc. Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
ES2655833T3 (es) * 2004-05-11 2018-02-21 AbGenomics Coöperatief U.A. Epítopos que inducen la muerte de células T
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
BRPI0512413A (pt) * 2004-06-23 2008-03-04 Childrens Hosp & Res Ct Oak derivados de polissacarìdeo e usos na indução de uma resposta imune
US8052971B2 (en) * 2005-11-21 2011-11-08 MG Biologics Oral use of specific antibodies for intestinal health
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
WO2007075921A2 (en) 2005-12-23 2007-07-05 Children's Hospital & Research Center At Oakland De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
AR058736A1 (es) * 2005-12-29 2008-02-20 Ct Ingenieria Genetica Biotech Peptidos mimeticos de carbohidratos y su empleo en formulaciones farmaceuticas
EP1976857A4 (en) * 2006-01-13 2011-08-03 Baxter Int PROCESS FOR CLEANING POLYSACCHARIDES
GB0606155D0 (en) * 2006-03-28 2006-05-10 Liverpool School Of Tropical M Bacterial vaccine
WO2007116409A2 (en) * 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2692069C (en) * 2007-06-20 2016-10-18 Baxter Healthcare S.A. Modified polysaccharides for conjugate vaccines
WO2009006620A1 (en) * 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Oligosialic acid derivatives, methods of manufacture, and immunological uses
AU2008272854B2 (en) * 2007-07-03 2014-03-13 Children's Hospital & Research Center At Oakland Inhibitors of polysialic acid de-N-acetylase and methods for using the same
WO2009006613A1 (en) * 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting
US20100285446A1 (en) * 2007-07-20 2010-11-11 Akos Vertes Methods for Detecting Metabolic States by Laser Ablation Electrospray Ionization Mass Spectrometry
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090156459A1 (en) * 2007-11-16 2009-06-18 Pharmain Corporation Cationic-Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2009117409A2 (en) * 2008-03-18 2009-09-24 Merck & Co., Inc. A high throughput protein interaction assay
TW201103980A (en) * 2009-07-08 2011-02-01 Abbott Biologicals Bv Viral vaccine and use thereof
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
WO2012054879A1 (en) * 2010-10-22 2012-04-26 Duke University Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia
JP2014524121A (ja) 2011-07-14 2014-09-18 ザ・ジョージ・ワシントン・ユニバーシティ レーザアブレーション・エレクトロスプレイイオン化質量分析用のプルームコリメーション
US10598666B2 (en) * 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
US9770504B2 (en) * 2013-05-03 2017-09-26 The Board Of Regents Of The University Of Texas System Generating peptoid vaccines
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4153999A1 (en) * 2020-05-19 2023-03-29 Laboratory Corporation of America Holdings Methods and systems for quantitative detection of antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
JPH0720878B2 (ja) * 1983-11-21 1995-03-08 ザ ウエルカム フアウンデ−シヨン リミテツド 改善された複合体、それらの製造法および該複合体を含有する製剤
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
EP0449958B9 (en) * 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine
SU1708846A1 (ru) * 1989-11-22 1992-01-30 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Штамм бактерий NeISSeRIa меNINGIтIDIS серогруппы В - продуцент капсульного полисахарида и полисахаридно-белкового комплекса
HU9201966D0 (en) 1989-12-14 1992-10-28 Ca Nat Research Council An improved vaccine of meningococcus-polysaccharide conjunction
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
JP4150082B2 (ja) 1996-08-27 2008-09-17 カイロン コーポレイション 独特の髄膜炎菌性ｂエピトープを規定するモノクローナル抗体およびワクチン組成物の調製におけるそれらの使用
ES2166097T5 (es) 1996-08-27 2007-03-16 Novartis Vaccines And Diagnostics, Inc. Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
ATE421527T1 (de) 1997-08-27 2009-02-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkus b epitopen

Also Published As

Publication number Publication date
US6048527A (en) 2000-04-11
JP4150082B2 (ja) 2008-09-17
EP0922059B1 (en) 2003-10-22
US7063949B2 (en) 2006-06-20
ATE252602T1 (de) 2003-11-15
US20060035284A1 (en) 2006-02-16
EP0922059A1 (en) 1999-06-16
US20040077840A1 (en) 2004-04-22
US20020197260A1 (en) 2002-12-26
JP2001500372A (ja) 2001-01-16
US7504254B2 (en) 2009-03-17
US6642354B2 (en) 2003-11-04
DE69725739D1 (de) 2003-12-11
CA2264585A1 (en) 1998-03-05
CA2264585C (en) 2005-06-14
JP2008044947A (ja) 2008-02-28
WO1998008874A1 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
DE69725739T2 (de) Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
EP1007546B1 (en) Molecular mimetics of meningococcal b epitopes
DE69735715T2 (de) Cholin-bindendes Protein, welches als gegen Pneumokokken gerichtetes Vakzin verwendet wird
DE60026691T2 (de) Staphylococcus-antigene und impstoffe
DE69333585T2 (de) Gereinigtes vakuolisierendes toxin aus helicobacter pylori und methoden zu dessen verwendung
DE69928384T2 (de) Behandlung und nachweis von staphylokokkeninfektionen
US20080139789A1 (en) Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
DE69535360T2 (de) Synthetische peptide und impfstoffe welche diese beinhalten
US7279162B1 (en) Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
Rukavina et al. Protective effect of antilipopolysaccharide monoclonal antibody in experimental Klebsiella infection
JPH0797395A (ja) ポルフイロモナス・ジンジバリス線毛蛋白質の配列を含有するペプチド類及びその用途
DE69630682T2 (de) Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
Virji et al. The potential protective effect of monoclonal antibodies to gonococcal outer membrane protein IA
DE69535156T2 (de) Verfahren und zusammensetzungen zur diagnose von rochalimaea henselae und rochalimaea quintana infektion
DE60133734T2 (de) Polypeptide die polymorphismen aus bordertella pertussis, bordetella parapertussis und bordetella bronchiseptica pertactin wiederholende regionen enthalten, ihre verwendung in diagnostik und immunogene zusammensetzungen
EP0663404B1 (de) Antikörper für den Nachweis von Salmonellen
CA2200691C (en) Broadly reactive opsonic antibodies reactive with common staphylococcal antigens
DE60022995T2 (de) Impfstoff
WO1996009321A9 (en) Broadly reactive opsonic antibodies reactive with common staphylococcal antigens
Biondo et al. Protective Immunization against

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLA, US

Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EM, US

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLA, US

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US